Loading…

CareDx, Inc.CDNACompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Diagnostics company making molecular tests that monitor organ transplant patients for rejection risk.

Momentum leader 99
Mkt cap
$3.91B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$98.9M
20-day average traded
Fwd P/E
50.6×
forward earnings
ROIC−WACC
-16.2 pp
WACC 17.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$74.44
1D-0.2%
1W-8.3%
1M+7.6%
3M+58.4%
6M+252.0%
YTD+295.1%
1Y+379.9%
ATR %6.6%
Beta1.25
52w lowhigh18.1% off high

What CareDx does

Diagnostics company making molecular tests that monitor organ transplant patients for rejection risk.

Earns per test run in its own labs for transplant centres, billed mostly to Medicare and private insurers rather than to hospitals directly, so insurance coverage and per-test payment rates decide results. Kidney transplant monitoring is the core; heart tests came alongside.

Products and services

  • AlloSure (donor-derived cell-free DNA test)
  • AlloMap (gene-expression rejection test)
  • Multi-organ AlloSure panels
  • Transplant patient management software

Customers

  • Transplant centers
  • Nephrologists
  • Cardiologists

Where it sits in the supply chain

  • Diagnostics
  • Transplant diagnostics
  • Molecular monitoring for organ…

What could go right

  • Transplant surveillance test adoption
  • New organ-type test launches

What could go wrong

  • Reimbursement/payer coverage risk
  • Competitive transplant diagnostics market

Moat: narrow (IP / patents, data, regulatory licence). Patented, clinically validated transplant-rejection tests with deep transplant-center relationships.

Headquarters: Brisbane, California · Founded: 1998 · Employees: 765

Named competitors

CareDx at a glance

Size CareDx (CDNA) is a United States Health Care company (Medical Specialties) with a market value of $3.91B, the 1351st largest of 3,085 United States companies the cockpit tracks. Shares closed at $74.44 on 18 Nov 2026.

Performance Over six months the shares gained 252.0%, against +11.1% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 38.9% over the last twelve months (peer median +7.4%); the operating margin is 0.9% (peer median 12.8%).

Valuation It trades at 50.6× forward earnings against a peer median of 21.5× (2nd most expensive of 19).

Capital Return on invested capital runs 16.2 points below its cost of capital (17.5% WACC).

Short interest Short interest is 13.7% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020030040021 May 202621 Aug 202618 Nov 2026CDNA 345Peer median 112
Six months, rebased to 100: CareDx against the median of its 20 peers (local-currency closes).

CareDx financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$497M$380M$334M$280M$322M
Revenue growth—+14%+19%-13%—
Gross profit$351M$254M$222M$176M$207M
EBITDA$28.0M-$1.71M-$33.5M-$82.1M-$61.2M
Net income$129M-$21.4M$52.5M-$190M-$76.6M
Free cash flow$59.8M$36.1M$31.6M-$26.7M-$46.5M
Capital expenditure$9.26M$6.59M$6.48M$9.24M$24.3M
Total debt$29.0M$26.2M$28.4M$34.2M$39.0M

Quarterly statements and history in the cockpit →

CareDx competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%FIE002432NVST1SXPSTVN603014TECN4203AMBU-BICUIAXGNPLSE603658TMDXGRAL688301SHC603301MMEDCDNA6-month return →1-month return →
Up and to the right = strong over both horizons. CareDx is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%25×50×75×FIE002432NVST1SXP002223STVNTECNAMBU-BAXGNTMDX688301603301MMEDCDNARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CareDx is the large dot.

CareDx competitors and peer comparison

Head to head with its named competitors (CDNA vs NTRA vs TMO vs ERF.PA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CareDx CDNA$3.91B+252%+39%1%50.6×n/a
Natera NTRA$42.0B+41%+37%-9%n/an/a
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Eurofins Scientific ERF.PA$16.4B+37%+3%12%22.1×12.9%

How CareDx compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CareDx against its 20 peers (data as of 18 Nov 2026)
MeasureCDNAPeer medianRank in peer set
1-month return+7.6%+3.5%9th highest of 21
6-month return+252.0%+11.1%highest of 21
Distance from 52-week high-18.1%-22.1%9th highest of 21
Revenue growth (TTM)+38.9%+7.4%3rd highest of 21
Operating margin0.9%12.8%5th lowest of 20
Forward P/E50.6×21.5×2nd most expensive of 19
ROIC minus cost of capital-16.2 pp-0.0 pp3rd lowest of 19
Net debt / EBITDA-7.9×1.0×least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
ICU Medical ICUIUnited States$4.46B+38%-6%8%19.4×18.9%+11.9%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
GRAIL GRALUnited States$4.59B+67%+17%-332%n/an/an/a
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Sotera Health SHCUnited States$4.65B+5%+7%37%15.7×14.4%+7.3%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a

Questions

Who are CareDx's main competitors?
Named competitors: Natera (NTRA), Thermo Fisher Scientific (TMO), Exact Sciences (private or unlisted), Eurofins Scientific (ERF.PA). The cockpit's measured peer set (industry) also includes Fielmann (FIE.DE), Andon Health (002432.SZ), Envista (NVST), SCHOTT Pharma AG & Co. KGaA (1SXP.DE), Jiangsu Yuyue Medical Equipment & Supply (002223.SZ), Stevanato (STVN).
Is CareDx expensive compared with its peers?
On forward p/e it trades at 50.6× against a peer median of 21.5×, 2nd most expensive of 19 in its peer set.
How has CareDx stock performed?
Over six months to 18 Nov 2026 the shares returned +252.0% against +11.1% for the median peer; over one year +379.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.